• Product NameTicagrelor
• Brief DescriptionInhibitors
• Purification99.50%
• Biological ActivityTicagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. Unlike clopidogrel, ticagrelor is not a prodrug and does not require metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011.
• Target NameOthers antagonist; P2 Receptor inhibitor; P450 antagonist
• CAS No. 274693-27-5
• Calculated MW 522.57
• Formulation C23H28F2N6O4S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cardiovascular System
  SMILES:CCCSC1=NC2=C(C(=N1)N[C@@H]3C[C@H]3C4=CC(=C(C=C4)F)F)N=NN2[C@@H]5C[C@@H]([C@H]([C@H]5O)O)OCCO
  Pathways:Metabolism; Neuroscience; Others
  Receptor:Midazolam 4-hydroxylation; P2Y12; CYP2C9
  Boling pt:777.551C
  Melting pt:
  Solubility:Ethanol: 53 mg/mL (101.42 mM); DMSO: 105 mg/mL (200.93 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Gebremeskel S, et al. Int J Y. 2015 Jan 1; 136(1):234-40.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting